Cure My Disease

Don't miss your cure!

 Log in / Sign up

RUDRA registry (Real-World clinical registry for patients with recurrent pericarditis)

NCT ID NCT06517966

NEW Sponsor: Eurasian Association of Therapists Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 10, 2026

Summary

А multicenter, non-interventional real world clinical registry of patients with recurrent pericarditis. The main goal of the registry is to epidemiologically assess the pattern, clinical outcomes, and approaches to therapy in patients with recurrent pericarditis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Anonymous male and female patients over 18 years of age suffering from recurrent pericarditis without an established etiology at the time of inclusion in the study (suspected "idiopathic recurrent pericarditis") or diagnosed with "idiopathic recurrent pericarditis"

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men or women 18 years of age or older at the time of data recording or pericarditis debut; 2. Presence of one of the following conditions: * a specialist-confirmed diagnosis of recurrent pericarditis without an established etiology at the time of inclusion in the study (suspected "idiopathic recurrent pericarditis"); * a specialist-confirmed diagnosis of "idiopathic recurrent pericarditis". Exclusion Criteria: 1. Age below 18 years at the time of inclusion in the registry or debut of pericarditis; 2. Specialist-confirmed secondary genesis of RP (infectious, autoimmune, neoplastic, metabolic, traumatic, iatrogenic, etc.); 2. Manifestations and complications of myocarditis, various diseases of thoracic organs, systemic diseases, cardiac surgery, radiation therapy, tuberculosis, etc.); 3. lack of possibility of screening examination and dynamic follow-up; 4. Organ/tissue transplantation less than 5 years prior to study inclusion or debut of pericarditis; 5. Oncologic disease less than 3 years prior to study inclusion or pericarditis debut; 6. Chemotherapy with anthracycline-type drugs at the time of pericarditis debut; 7. Administration of amphetamine-type drugs at the time of pericarditis debut; 8. Cardiac/pericardial surgery in the last 6 months prior to study inclusion or pericarditis debut; 9. Myocardial infarction in the last 3 months prior to study inclusion or debut of pericarditis; 10. Traumatic chest injury in the last 3 months prior to study inclusion or pericarditis debut; 11. Absence of an informed consent form signed by the patient for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pericarditis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pericarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pericarditis

Contacts and locations

Locations

  • Eurasian Association of Therapists

    Moscow, 11000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.